Zydus Cadila receives tentative approval from USFDA for Eluxadoline Tablets


Zydus Cadila’s U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the USFDA to market Eluxadoline Tablets in the strengths of 75 mg and 100 mg, company said in the release.

Zydus’ Eluxadoline Tablets are indicated in adults for the treatment of irritable bowel syndrome with diarrhea, or IBS-D. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

Cadila Healthcare was quoting at Rs 489.40, down Rs 2.70, or 0.55 percent.

News Source: MoneyControl

For Enquiry Fill The Form

    *Note:- Please provide a valid Email Id to receive OTP from bigprofitbuzz.com.

    Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button